Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7CWQY)

Drug Name

PUNICAFOLIN Drug Info

Synonyms

Punicafolin; 88847-11-4; CHEMBL507308; 1,2,4-Tri-O-galloyl-3,6-hexahydroxydiphenoylglucose; beta-D-Glucopyranose, cyclic 3,6-(4,4',5,5',6,6')-hexahydroxy(1,1'-biphenyl)-2,2'-dicarboxylate) 1,2,4-tris(3,4,5-trihydroxybenzoate), (R)-; 1,2,4-tri-O-galloyl-3,6-(R)-hexahydroxydiphenoyl-; .beta.-D-Glucopyranose, cyclic 3:6-bis[(1S)-4,4',5,5',6,6'-hexahydroxy[1,1'-biphenyl]-2,2'-dicarboxylate] 1,2,4-tri(3,4,5-trihydroxybenzoate)

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 5320800
CAS Number: CAS 88847-11-4
TTD Drug ID: DM7CWQY

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Protein kinase C alpha (PRKCA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sodium phenylbutyrate	DMXLBCQ	Spinal muscular atrophy	8B61	Approved	[2]
Sotrastaurin acetate	DME53YS	Renal transplantation	NE84	Phase 2	[3]
PMID28460551-Compound-3	DMA1FRM	N. A.	N. A.	Patented	[4]
ISIS 3521	DMZFS69	N. A.	N. A.	Discontinued in Phase 2	[5]
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[6]
RO-320432	DMFZ1YW	N. A.	N. A.	Terminated	[7]
LY-317644	DMM20PI	N. A.	N. A.	Terminated	[8]
Acteoside	DM0YHKB	Nephritis	GB40	Terminated	[9]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[10]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Protein kinase C beta (PRKCB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Enzastaurin	DM5H0R9	Diffuse large B-cell lymphoma	2A81	Phase 3	[12]
RUBOXISTAURIN HYDROCHLORIDE	DMQOCD8	Lymphoma	2A80-2A86	Phase 3	[13]
Sotrastaurin acetate	DME53YS	Renal transplantation	NE84	Phase 2	[3]
LY333531	DMGMC8H	Solid tumour/cancer	2A00-2F9Z	Phase 2	[14]
MS-553	DM7ER9J	Chronic lymphocytic leukaemia	2A82.0	Phase 1	[15]
Linetastine	DMF8B62	Rhinitis	FA20	Discontinued in Phase 2	[16]
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[6]
RO-320432	DMFZ1YW	N. A.	N. A.	Terminated	[7]
LY-317644	DMM20PI	N. A.	N. A.	Terminated	[8]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Protein kinase C alpha (PRKCA)	TTFJ8Q1	KPCA_HUMAN	Inhibitor	[1]
Protein kinase C beta (PRKCB)	TTYPXQF	KPCB_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Tannins as selective inhibitors of protein kinase C, Bioorg. Med. Chem. Lett. 2(3):239-244 (1992).
2	Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.Mol Cancer Ther. 2013 Aug;12(8):1393-401.
3	Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
4	Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
5	Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.Lung Cancer.2006 May;52(2):173-80.
6	Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
7	Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
8	Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
9	Phenylethanoid glycosides from Digitalis purpurea and Penstemon linarioides with PKCalpha-inhibitory activity. J Nat Prod. 1998 Nov;61(11):1410-2.
10	Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
11	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
12	The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma. 2008 Jul;49(7):1374-83.
13	Ruboxistaurin: LY 333531. Drugs R D. 2007;8(3):193-9.
14	Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes. 2003 Feb;52(2):512-8.
15	ClinicalTrials.gov (NCT03492125) A Study Of The Selective PKC-beta Inhibitor MS- 553. U.S. National Institutes of Health.
16	Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol. 2002 May;133(5):693-8.